NEJM March 2026: Volume 394, Issue 11 – Latest Research

A long-term study following men across Europe for 23 years offers further insight into the benefits and potential harms of prostate cancer screening. Published in the New England Journal of Medicine on March 12, 2026, the research adds to the ongoing debate about whether widespread prostate-specific antigen (PSA) testing is an effective way to reduce deaths from this common cancer. The study, detailed in Volume 394, Issue 11, provides a nuanced picture, suggesting a modest reduction in prostate cancer deaths, but as well highlighting the potential for overdiagnosis and overtreatment.

The ERSPC Study: A 23-Year Perspective

The European Randomized Study of Screening for Prostate Cancer (ERSPC), initiated in the early 2000s, enrolled over 162,000 men aged 50 to 74 across eight European countries. Participants were randomly assigned to either receive PSA-based screening or usual care. The initial findings, published years ago, indicated a potential benefit from screening, but the long-term follow-up – now spanning two decades and three years – provides a more complete assessment. This latest analysis focuses on mortality rates and the implications of widespread screening programs.

Prostate cancer is a malignancy that develops in the prostate gland, a small walnut-shaped organ in men that produces seminal fluid. PSA is a protein produced by the prostate, and elevated levels in the blood can indicate the presence of cancer, but also benign conditions like inflammation or an enlarged prostate. This is a key reason why interpreting PSA test results can be complex and why overdiagnosis is a concern.

Who Does This Affect?

The findings primarily affect men aged 50 and older, the age group targeted by most prostate cancer screening programs. The ERSPC study population was largely European, so the results may not be directly generalizable to men of different ethnicities or geographic regions. However, prostate cancer incidence rates are similar across many Western countries, making the findings relevant to a broad population. The study’s implications are particularly important for healthcare systems considering or already implementing national prostate cancer screening initiatives. Currently, screening recommendations vary significantly between countries.

Evidence and Limitations: Weighing the Benefits

The 23-year follow-up data revealed that men who participated in PSA screening had a 13% reduction in the risk of death from prostate cancer compared to those who received usual care. While statistically significant, this reduction is relatively modest. Researchers emphasize that this benefit comes with a trade-off. Screening led to a higher rate of prostate cancer diagnoses, many of which were slow-growing and unlikely to cause harm during a man’s lifetime – a phenomenon known as overdiagnosis.

Overdiagnosis can lead to overtreatment, which often involves surgery or radiation therapy. These treatments carry potential side effects, including urinary incontinence, erectile dysfunction, and bowel problems. The ERSPC study acknowledges that the increased detection of non-aggressive cancers contributed to a higher number of men undergoing treatment they may not have needed. A key limitation of the study is the varying screening protocols and treatment practices across the participating countries. This heterogeneity makes it difficult to isolate the specific impact of screening from other factors influencing prostate cancer outcomes. The study did not assess the quality of life impacts associated with screening and treatment.

Understanding the Numbers: Relative vs. Absolute Risk

The reported 13% reduction in prostate cancer mortality is a relative risk reduction. Which means that for every 1,000 men screened, approximately one fewer death from prostate cancer occurred compared to those not screened. This translates to an absolute risk reduction of about 0.1%. It’s crucial to understand this distinction. While a 13% reduction sounds substantial, the actual benefit at the individual level is small. The baseline risk of dying from prostate cancer varies depending on factors like age, family history, and ethnicity. For example, African American men have a higher risk of developing and dying from prostate cancer than Caucasian men. The American Cancer Society provides detailed statistics on prostate cancer incidence and mortality.

What Does This Mean for Patients?

The ERSPC findings do not provide a definitive answer to the question of whether or not to screen for prostate cancer. Instead, they underscore the importance of shared decision-making between men and their doctors. Men should be informed about the potential benefits and harms of PSA screening and should consider their individual risk factors and preferences. Those with a strong family history of prostate cancer or who are concerned about their risk may be more inclined to undergo screening, while others may choose to forego it. It’s important to remember that PSA testing is not a perfect test and can yield false-positive results, leading to unnecessary anxiety and further testing.

Public Health Implications and Guidance Updates

The ERSPC study is likely to inform ongoing discussions among public health organizations and medical societies regarding prostate cancer screening guidelines. Organizations like the U.S. Preventive Services Task Force (USPSTF) regularly review the evidence and update their recommendations. Currently, the USPSTF recommends against routine PSA-based screening for all men, but acknowledges that individual circumstances may warrant a discussion with a doctor. The USPSTF’s current recommendations are available on their website. The European Association of Urology (EAU) also provides guidelines on prostate cancer screening and management.

Looking Ahead: Ongoing Research and Surveillance

Further research is needed to identify biomarkers that can more accurately predict which cancers are aggressive and require treatment, and which are slow-growing and can be safely monitored. Advances in imaging techniques, such as multiparametric MRI, are also helping to improve the accuracy of prostate cancer diagnosis. Ongoing surveillance programs are essential to monitor prostate cancer incidence and mortality rates and to assess the impact of screening initiatives. Researchers are also exploring the potential of new screening strategies, such as combining PSA testing with other biomarkers or using risk prediction models to personalize screening recommendations. The long-term follow-up of the ERSPC study will continue to provide valuable insights into the complex relationship between prostate cancer screening, diagnosis, and outcomes.